- Founded: 2015
- CEO: Kevin Eisenfrats
- Size of Facility: 4600 sq ft
- Company Size: 8
- Funding Source: Grants (e.g. SBIR, CRCF, CIT), Investor Funded, Venture Captital/Private Equity
- Development Stage: Pre-clinical
Contraline is an early-stage biotechnology company developing the first long-lasting, non-hormonal, and reversible form of male birth control. Our first product, Echo-V, is a polymer gel that is implanted non-surgically into the vas deferens via a novel medical procedure called Vasintomy. We conduct research and development in our laboratory in Charlottesville, VA and in partnership with academic institutions, including the University of Virginia.